Next Article in Journal
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2012, 5(12), 1346-1371; doi:10.3390/ph5121346
Review

Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent

1
, 1
, 2
, 3
 and 1,*
Received: 6 November 2012; in revised form: 16 November 2012 / Accepted: 30 November 2012 / Published: 5 December 2012
(This article belongs to the Special Issue Cyclooxygenase(COX) Inhibitors)
View Full-Text   |   Download PDF [446 KB, updated 6 December 2012; original version uploaded 5 December 2012]   |   Browse Figures
Abstract: Recent findings have shown that aspirin, taken for several years, reduces the long-term risk of some cancers, particularly colorectal cancer. The result that aspirin benefit is detectable at daily low-doses (at least 75mg), the same used for the prevention of cardiovascular disease, positions the antiplatelet action of aspirin at the center of its antitumor efficacy. At low-doses given every 24 h, aspirin is acting by a complete and persistent inhibition of cyclooxygenase (COX)-1 in platelets (in the pre-systemic circulation) while causing a limited and rapidly reversible inhibitory effect on COX-2 and/or COX-1 expressed in nucleated cells. Aspirin has a short half-life in human circulation (approximately 20 min); nucleated cells have the ability to resynthesize the acetylated COX-isozymes within a few hours, while platelets do not. COX-independent mechanisms of aspirin, such as the inhibition of Wnt/ b-catenin and NF-kB signaling and the acetylation of extra-COX proteins, have been suggested to play a role in its chemo-preventive effects, but their relevance remains to be demonstrated in vivo at clinical doses. In conclusion, the results of clinical pharmacology and the analysis of randomized and epidemiological studies suggest that colorectal cancer and atherothrombosis share a common mechanism of disease, i.e. enhanced platelet activation in response to injury at distinct sites.
Keywords: aspirin; colorectal cancer; platelet; cycloooxygenase-1 aspirin; colorectal cancer; platelet; cycloooxygenase-1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Dovizio, M.; Tacconelli, S.; Sostres, C.; Ricciotti, E.; Patrignani, P. Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent. Pharmaceuticals 2012, 5, 1346-1371.

AMA Style

Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P. Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent. Pharmaceuticals. 2012; 5(12):1346-1371.

Chicago/Turabian Style

Dovizio, Melania; Tacconelli, Stefania; Sostres, Carlos; Ricciotti, Emanuela; Patrignani, Paola. 2012. "Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent." Pharmaceuticals 5, no. 12: 1346-1371.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert